Valeant Pharmaceuticals collaborates with Bausch + Lomb, IBM

Valeant Pharmaceuticals International, Inc.´s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, and IBM (NYSE: IBM) today announced a collaboration to develop the first app of its kind for iPhone and iPad to assist surgeons who perform cataract surgery, the company said.

The innovative app will help surgeons streamline their workflow by delivering patient information and clinical insights as well as intraocular lens (IOL) selection guidance on a single digital platform at the point of care.

The app will be designed to electronically manage patient data across iPhone and iPad while hosting health-related data on IBM Cloud — a secure, cloud-based environment — and relaying informed, customized IOL options to surgeons that they will use to help enhance surgical planning and provide better patient care. The MobileFirst for iOS team, which is part of IBM Global Business Services, will design and develop this custom app for Bausch + Lomb to help drive innovation in healthcare. Bausch + Lomb´s vision is to optimize the app to collect data over time, resulting in a cognitive app that applies machine-based learning and predictive analytics to deliver real-time insights to surgeons.

Pilot study testing for the new application is expected to begin in late 2016.

Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics.